VT-464

Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM) and an AR antagonist. Seviteronel demonstrates both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition.


Cat. No.: EX-A5986	Purity: >98%

	Chemical structure of VT-464

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	Seviteronel
CAS No.	1610537-15-9
Purity	>98%
Formula	C18H17F4N3O3
Mol Weight	399.3395
Color	White to light yellow
State	solid powder
Solubility	Soluble in DMSO ? 50 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20 ℃, 3 years; 4℃ 2 year; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Rafferty SW, et al. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2444-7. [2]. Sankar N. Maity, et al. Abstract 4772: Efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20-lyase, in castrate-resistant prostate cancer models. Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1 [3]. Michmerhuizen AR, et al. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. Front Endocrinol (Lausanne). 2020 Feb 11;11:35.
CoA	CoA of VT-464


		Search